


1 **Supplementary Figure S5**



2 **C**

Antibody (Clone 9D9)	αCTLA-4 (mIgG2b)			αCTLA-4 ^{DLE} (mIgG2b.DLE)		
Dose (µg)	10	30	100	10	30	100
C _{max} (µg/mL)	5.3	15.4	53.9	4.6	14.4	35.7
T _{max} (h)	6	6	3	9	6	9
T _{1/2} (h)	60.0	52.9	54.1	49.9	44.8	48.4
AUC _{0-last} (h*µg/mL)	372.3	1157.4	4142.1	261.9	925.0	2751.9
V _z (mL)	2.3	2.0	1.9	2.7	2.1	2.5
Cl (mL/h)	0.027	0.026	0.024	0.038	0.032	0.036
Lambda z (1/h)	0.012	0.013	0.013	0.014	0.015	0.014

3

4 **Supplementary Figure S5. Pharmacokinetics of mouse αCTLA-4^{DLE}.** Concentration – time

5 curves from plasma collected at indicated time points from Balb/c mice administered 10, 30 or

6 100 µg of **(a)** αCTLA-4 (clone 9D9, αCTLA-4) or **(b)** Fc-enhanced αCTLA-4 (clone 9D9, αCTLA-

7 4^{DLE}) antibodies on study day 0. Plasma drug concentrations were quantified using a qualified

8 ligand capture ELISA assay. **(c)** Pharmacokinetic parameter from a non-compartmental analysis

9 (NCA) analysis performed on concentration - time data from **(a)** and **(b)**. Abbreviations. C_{max},

10 concentration maximum; T_{max}, time maximum; T_{1/2}, half-life; AUC, area under the curve; V_z,

volume of distribution; Cl, clearance.